Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by valentinemassonon May 26, 2020 12:34am
259 Views
Post# 31071614

RE:RE:RE:RE:RE:RE:RE:Relax time

RE:RE:RE:RE:RE:RE:RE:Relax time
Liked2Think wrote: I have super high expectation for this stock but calling for a dollar right now when the last news wasnt good is not a good idea and is setting unrealistic expections even for the rest of this year and likely next.

Saying we should be equivalent to MIR is also a mistake.  Do I think Stage has a better approach than MIR and have a better plan? yes but the fact of the matter we are at $0.095 a share right now and they arent.

Yes i know lots of wood being put on a lot of fires to get this company going but I ask to hold realistic expections and curb the "too the moon" talk we saw on this board after the conference call before we had Q4 results.
Everyone should have known the earnings would not be stellar.Costs money to make money, aka clinical trials and tests. With Covid testing on the radar , a viable partnership and inroad to the US market, as well testing in a controlled group in Western Canada says that someone is doing their job . What is unique of SZLS is their method of testing. MIR does not offer the same, nor does Sona . All IMO. VM .

Bullboard Posts